Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer

Giuseppe Curigliano; Geoffrey I. Shapiro; Rebecca S. Kristeleit; Albiruni R. Abdul Razak; Stephen Leong; Maria Alsina; Antonio Giordano; Karen A. Gelmon; Erica Stringer-Reasor; Ulka N. Vaishampayan; Mark Middleton; Anthony J. Olszanski; Hope S. Rugo; Kenneth A. Kern; Nuzhat Pathan; Rachelle Perea; Kristen J. Pierce; Sarah C. Mutka; Zev A. Wainberg

doi:10.1038/s41416-023-02161-w

Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer

Giuseppe Curigliano
, Geoffrey I. Shapiro
, Rebecca S. Kristeleit
, Albiruni R. Abdul Razak
, Stephen Leong
, Maria Alsina
, Antonio Giordano
, Karen A. Gelmon
, Erica Stringer-Reasor
, Ulka N. Vaishampayan
, Mark Middleton
, Anthony J. Olszanski
, Hope S. Rugo
, Kenneth A. Kern
, Nuzhat Pathan
, Rachelle Perea
, Kristen J. Pierce
, Sarah C. Mutka
, Zev A. Wainberg

IRCCS Istituto Europeo di Oncologia - Milano
University of Milan
Dana-Farber Cancer Institute
University College London
Princess Margaret Cancer Centre
University of Colorado Anschutz Medical Campus
Vall d'Hebron Institute of Oncology
Hollings Cancer Center
British Columbia Cancer Agency
University of Alabama at Birmingham
University of Michigan, Ann Arbor
University of Oxford
University of California at San Francisco
Pfizer
Celcuity
University of California at Los Angeles

Research output: Contribution to journal › Comment/debate

Abstract

The original version of this article contained an error in an affiliation. As per Italian regulation, the two affiliations for Dr. Curigliano (Istituto Europeo di Oncologia, IRCCS and University of Milan, Milano, Italy) must be separated out for proper accreditation within their systems. The original article has been corrected.

Original language	English
Pages (from-to)	400
Number of pages	1
Journal	British Journal of Cancer
Volume	128
Issue number	2
DOIs	https://doi.org/10.1038/s41416-023-02161-w
State	Published - Jan 19 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41416-023-02161-w

Cite this

Curigliano, G., Shapiro, G. I., Kristeleit, R. S., Abdul Razak, A. R., Leong, S., Alsina, M., Giordano, A., Gelmon, K. A., Stringer-Reasor, E., Vaishampayan, U. N., Middleton, M., Olszanski, A. J., Rugo, H. S., Kern, K. A., Pathan, N., Perea, R., Pierce, K. J., Mutka, S. C., & Wainberg, Z. A. (2023). Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. British Journal of Cancer, 128(2), 400. https://doi.org/10.1038/s41416-023-02161-w

@article{ed666c87a5cb47aa9f791c3c84260b59,

title = "Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer",

abstract = "The original version of this article contained an error in an affiliation. As per Italian regulation, the two affiliations for Dr. Curigliano (Istituto Europeo di Oncologia, IRCCS and University of Milan, Milano, Italy) must be separated out for proper accreditation within their systems. The original article has been corrected.",

author = "Giuseppe Curigliano and Shapiro, \{Geoffrey I.\} and Kristeleit, \{Rebecca S.\} and \{Abdul Razak\}, \{Albiruni R.\} and Stephen Leong and Maria Alsina and Antonio Giordano and Gelmon, \{Karen A.\} and Erica Stringer-Reasor and Vaishampayan, \{Ulka N.\} and Mark Middleton and Olszanski, \{Anthony J.\} and Rugo, \{Hope S.\} and Kern, \{Kenneth A.\} and Nuzhat Pathan and Rachelle Perea and Pierce, \{Kristen J.\} and Mutka, \{Sarah C.\} and Wainberg, \{Zev A.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Nature Limited 2023.",

year = "2023",

month = jan,

day = "19",

doi = "10.1038/s41416-023-02161-w",

language = "English",

volume = "128",

pages = "400",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "2",

}

Curigliano, G, Shapiro, GI, Kristeleit, RS, Abdul Razak, AR, Leong, S, Alsina, M, Giordano, A, Gelmon, KA, Stringer-Reasor, E, Vaishampayan, UN, Middleton, M, Olszanski, AJ, Rugo, HS, Kern, KA, Pathan, N, Perea, R, Pierce, KJ, Mutka, SC & Wainberg, ZA 2023, 'Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer', British Journal of Cancer, vol. 128, no. 2, pp. 400. https://doi.org/10.1038/s41416-023-02161-w

Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. / Curigliano, Giuseppe; Shapiro, Geoffrey I.; Kristeleit, Rebecca S. et al.
In: British Journal of Cancer, Vol. 128, No. 2, 19.01.2023, p. 400.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer

AU - Curigliano, Giuseppe

AU - Shapiro, Geoffrey I.

AU - Kristeleit, Rebecca S.

AU - Abdul Razak, Albiruni R.

AU - Leong, Stephen

AU - Alsina, Maria

AU - Giordano, Antonio

AU - Gelmon, Karen A.

AU - Stringer-Reasor, Erica

AU - Vaishampayan, Ulka N.

AU - Middleton, Mark

AU - Olszanski, Anthony J.

AU - Rugo, Hope S.

AU - Kern, Kenneth A.

AU - Pathan, Nuzhat

AU - Perea, Rachelle

AU - Pierce, Kristen J.

AU - Mutka, Sarah C.

AU - Wainberg, Zev A.

PY - 2023/1/19

Y1 - 2023/1/19

N2 - The original version of this article contained an error in an affiliation. As per Italian regulation, the two affiliations for Dr. Curigliano (Istituto Europeo di Oncologia, IRCCS and University of Milan, Milano, Italy) must be separated out for proper accreditation within their systems. The original article has been corrected.

AB - The original version of this article contained an error in an affiliation. As per Italian regulation, the two affiliations for Dr. Curigliano (Istituto Europeo di Oncologia, IRCCS and University of Milan, Milano, Italy) must be separated out for proper accreditation within their systems. The original article has been corrected.

UR - https://www.scopus.com/pages/publications/85146754248

U2 - 10.1038/s41416-023-02161-w

DO - 10.1038/s41416-023-02161-w

M3 - Comment/debate

C2 - 36697966

AN - SCOPUS:85146754248

SN - 0007-0920

VL - 128

SP - 400

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 2

ER -

Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this